Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.42 |
| ▸ | PHGDH | O43175 | 2/20 | 0.42 |
| ▸ | IDH2 | P48735 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29627127 | 1.00 | CNR2 (0.44) | CNR2MALT1PHGDHIDH2THRB | |
| SCHEMBL7880036 | 0.83 | SCD (0.53) | CNR2MALT1PHGDHIDH2THRB | |
| SCHEMBL7875686 | 0.81 | CNR2 (0.49) | CNR2PHGDHTHRBLMNAMAPT | |
| SCHEMBL9310804 | 0.79 | MALT1 (0.52) | CNR2MALT1PHGDHIDH2LMNA | |
| SCHEMBL1420520 | 0.69 | MALT1 (0.66) | MALT1PHGDHIDH2LMNAMAPT | |
| SCHEMBL12969653 | 0.68 | IDH2 (0.73) | MALT1PHGDHIDH2LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL1669945 | 0.68 | MALT1 (0.64) | MALT1PHGDHIDH2LMNAMAPT | |
| SCHEMBL9312390 | 0.67 | PHGDH (0.47) | MALT1PHGDHIDH2LMNAMAPT | |
| Hydrochloric Acid SCHEMBL9309723 | 0.67 | PHGDH (0.46) | MALT1PHGDHIDH2LMNAMAPT | |
| SCHEMBL7875719 | 0.67 | SCD (0.55) | CNR2MAPTRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330292-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | Amgen, Inc (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9988457-B2 | Human C-FMS antigen binding proteins | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-2188313-B1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20160340434-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2016-11-24 | — | — | US | disclosed |
| US-9303084-B2 | Human C-FMS antibodies | AMGEN INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-1922337-B1 | TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIES | AMGEN INC (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-1648998-B1 | SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR | AMGEN INC (US) | 2014-10-01 | — | — | EP | disclosed |
| CN-101495513-B | Angiopoietin-2 specific binding agents | AMGEN INC | 2014-08-06 | — | — | CN | disclosed |
| CN-103880955-A | Specific binding agents to hepatocyte growth factor | AMGEN INC | 2014-06-25 | — | — | CN | disclosed |
| US-20140154243-A1 | SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR | AMGEN FREMONT INC. (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2007095583-A2 | METHODS FOR TREATING CANCER AND SENSITIZING CANCER CELLS USING THE SERINE PROTEASE INHIBITOR, MASPIN | CHILDREN'S MEMORIAL RESEARCH CENTER (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070179086-A1 | Polypeptides and antibodies | AMGEN INC. | 2007-08-02 | — | — | US | disclosed |
| EP-1805219-A1 | ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS | Amgen, Inc (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070087394-A1 | Epidermal growth factor receptor gene copy number | SIENA SALVATORE | 2007-04-19 | — | — | US | disclosed |
| EP-1773817-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006045049-A1 | ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006012374-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060018909-A1 | Angiopoietin-2 specific binding agents | AMGEN INC. | 2006-01-26 | — | — | US | disclosed |
| US-20050118643-A1 | Specific binding agents to hepatocyte growth factor | AMGEN INC | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | EDNRA, PTGIS, EDNRB | CNR2 83/4885MALT1 1099/4885PHGDH 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.